The Effect of Five Smoking Cessation Pharmacotherapies on Smoking Cessation Milestones

Sandra J. Japuntich
Harvard Medical School and University of Wisconsin School of Medicine and Public Health

Megan E. Piper
University of Wisconsin School of Medicine and Public Health

Adam M. Leventhal
University of Southern California Keck School of Medicine

Daniel M. Bolt
University of Wisconsin—Madison

Timothy B. Baker
University of Wisconsin School of Medicine and Public Health

Objective: Most smoking cessation studies have used long-term abstinence as their primary outcome measure. Recent research has suggested that long-term abstinence may be an insensitive index of important smoking cessation mechanisms. The goal of the current study was to examine the effects of 5 smoking cessation pharmacotherapies using Shiffman et al.’s (2006) approach of examining the effect of smoking cessation medications on 3 process markers of cessation or smoking cessation milestones: initial abstinence, lapse, and the lapse–relapse transition. Method: The current study (N = 1,504; 58.2% female and 41.8% male; 83.9% Caucasian, 13.6% African American, 2.5% other races) examined the effect of 5 smoking cessation pharmacotherapy treatments versus placebo (bupropion, nicotine lozenge, nicotine patch, bupropion + lozenge, patch + lozenge) on Shiffman et al.’s smoking cessation milestones over 8 weeks following a quit attempt. Results: Results show that all 5 medication conditions decreased rates of failure to achieve initial abstinence and most (with the exception of the nicotine lozenge) decreased lapse risk; however, only the nicotine patch and bupropion + lozenge conditions affected the lapse-relapse transition. Conclusions: These findings demonstrate that medications are effective at aiding initial abstinence and decreasing lapse risk but that they generally do not decrease relapse risk following a lapse. The analysis of cessation milestones sheds light on important impediments to long-term smoking abstinence, suggests potential mechanisms of action of smoking cessation pharmacotherapies, and identifies targets for future treatment development.

Keywords: smoking cessation, pharmacotherapy, medication, relapse, milestones

Much smoking cessation research has used long-term abstinence to evaluate the efficacy of cessation treatments. Recently, Shiffman et al. (2006) introduced the notion that successful cessation may be viewed as being dependent upon several component events that they term milestones. These include the ability to stop smoking (achieve short-term abstinence), avoid a lapse (smoking on a single day), and if a lapse occurs, avoid a relapse (a return to daily smoking; Shiffman et al., 2006). Parsing the multicomponent process of smoking cessation into meaningful subunits may provide insight into the process of cessation and relapse and provide guidance for the development and administration of smoking cessation treatments. The current study evaluates the effects of five smoking cessation pharmacotherapy treatments on smoking cessation milestones.
The majority of smoking cessation research has focused on a single type of outcome, long-term abstinence, defined as the absence of smoking within a period of 1 week prior to a distant follow-up time point (e.g., at 6 months after a quit attempt; Hughes et al., 2003). Recent research has suggested that this type of outcome reflects an amalgam of different cessation events or processes (Piatecki, 2006; Piatecki, Fiore, McCarthy, & Baker, 2002; Shiffman et al., 2006) that have rarely been explored in cessation studies. For example, most studies have not established whether participants were able to quit (i.e., abstain from smoking for at least 24 hr) during a cessation attempt. In addition, many studies have not separated out those smokers who lapsed and then returned to abstinence from those who lapsed and then reverted to regular smoking (i.e., relapsed). Thus, long-term abstinence, as it has been measured, may be an insensitive outcome by which to measure relations between cessation treatments and cessation processes (Piatecki, 2006; Piatecki et al., 2002; Shiffman et al., 2006).

Smoking Cessation Milestones

As noted above, Shiffman et al. (2006) suggested three discriminable smoking cessation events: achieving initial abstinence, lapsing, and the lapse–relapse transition. They argued that these milestones may reflect the influence of different causal processes that might be differentially sensitive to treatments. In support of this hypothesis, Shiffman et al. found that the high-dose nicotine patch had a larger effect on the transition from lapse to relapse than on other milestones (although being on the active high-dose patch treatment was associated with achievement of all milestones).

The aim of the current research is to characterize the effects of different smoking cessation pharmacotherapies on smoking cessation milestones. Although Shiffman et al. (2006) contributed to our understanding of how one treatment affects abstinence outcomes, their work had limitations. First, it examined only one investigational treatment (the high-dose nicotine patch). The current work examines five pharmacotherapy treatments, several of which are in widespread use. If milestones reflect different causal influences, and treatments vary in mechanisms, treatments may differ in their relations with milestones. For instance, this research tests two combination pharmacotherapies that have been shown to be significantly more effective than monotherapies in producing long-term abstinence (Piper et al., 2009; Smith et al., 2009). The current research will allow us to conduct relatively fine-grained analyses regarding the source of any added benefit of combination pharmacotherapies (e.g., higher initial cessation, lower lapse rates). Second, Shiffman et al. examined smoking cessation milestones for a relatively brief interval after the quit attempt (5 weeks). Some cessation processes (e.g., the resolution of a lapse) may unfold over an extended period of time; a longer period of study may yield more informative results. Third, the Shiffman et al. study had a fairly high drop-out rate (21% before treatment; 28% during treatment).

Treatment and Prediction of Cessation Milestones

The current study uses the Shiffman et al. (2006) paradigm to evaluate treatment effects on cessation milestones in individuals receiving one of five pharmacotherapy treatments versus placebo: the nicotine patch, the nicotine lozenge, bupropion, bupropion + nicotine lozenge, or nicotine patch + nicotine lozenge. These pharmacotherapies might produce different effects on the milestones, in part, because of differences in dosing parameters and therapeutic mechanism. Bupropion is started 1 week prior to the quit date to reach a therapeutic dose of the drug before the quit attempt (Hurt et al., 1997). Nicotine replacement therapies are generally started on the quit day. Therefore, although any of the medications might increase initial cessation, bupropion might produce higher rates of initial abstinence than nicotine replacement therapies because individuals initiate quit attempts with therapeutic levels of drug in the body. As Shiffman et al. noted, lapsing is often associated with exposure to smoking cues (Caggiula et al., 2001, 2002; Conklin, 2006; Conklin, Robin, Perkins, Salkeld, & McClernon, 2008; McCarthy, Piatecki, Fiore, & Baker, 2006; Shiffman, 2006). This suggests that PRN (pro re nata, or as-needed) medications (e.g., the nicotine lozenge) might show strong effects on lapsing because they could be taken during high-risk situations (e.g., during a stressful event). Finally, non-PRN pharmacotherapies are purported to work by reducing the rewarding properties of cigarettes (West, Baker, Cappelleri, & Bushmakin, 2008). This hypothesis is consistent with the Shiffman et al. finding that the high-dose nicotine patch was effective at reducing the risk of transition from lapse to relapse. The simple dosing parameters of non-PRN treatments may promote adherent use and more consistent therapeutic levels of drug when lapses occur. In sum, non-PRN pharmacotherapies (i.e., bupropion, nicotine patch) could decrease the risk of transition from lapse to relapse more effectively than do other agents.

Combination pharmacotherapies produce greater long-term abstinence rates than do monotherapies in head-to-head comparisons (Piper et al., 2007; Smith et al., 2009; Fiore et al., 2008). In this study, the combination pharmacotherapies comprise both PRN and non-PRN administration schedules, increasing the likelihood that the combinations may significantly affect all milestones. Further, the combinations might be superior to monotherapies by producing higher doses of the therapeutic agent (the nicotine patch + lozenge) or delivering multiple agents (bupropion + lozenge). Therefore, the combination treatments may be effective at boosting success rates at each milestone.

In sum, we hypothesized that, compared with placebo, (a) bupropion would increase initial abstinence rates; (b) the nicotine lozenge would reduce lapse risk; (c) bupropion and nicotine patch would reduce relapse risk following a lapse; and (d) combination pharmacotherapies (bupropion + lozenge, patch + lozenge) would produce beneficial effects relative to the monotherapies at each of the milestones (e.g., increase initial abstinence rates, reduce lapse risk, and reduce relapse risk following a lapse).

Method

Participants

Participants were 1,504 smokers (58.2% female and 41.8% male; 83.9% Caucasian, 13.6% African American, and 2.5% other races; see Table 1 for more demographics) from Southeastern Wisconsin who were participating in a clinical trial (Piper et al., 2009). Participants were recruited via television, radio, and newspaper advertisements, flyers, and media coverage. Inclusion criteria included smoking more than nine cigarettes per day for the past 6 months and being motivated to quit smoking. Exclusion criteria...
Table 1
Demographics and Descriptive Statistics

<table>
<thead>
<tr>
<th>Measure</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>% female</td>
<td>58.2</td>
</tr>
<tr>
<td>% male</td>
<td>41.8</td>
</tr>
<tr>
<td>Education</td>
<td></td>
</tr>
<tr>
<td>% &lt; high school</td>
<td>5.6</td>
</tr>
<tr>
<td>% high school</td>
<td>23.6</td>
</tr>
<tr>
<td>% some college</td>
<td>48.4</td>
</tr>
<tr>
<td>% ≥ college</td>
<td>21.9</td>
</tr>
<tr>
<td>Marital status</td>
<td></td>
</tr>
<tr>
<td>% married/live-in partner/widowed</td>
<td>56.8</td>
</tr>
<tr>
<td>% divorced/separated</td>
<td>24.2</td>
</tr>
<tr>
<td>% never married</td>
<td>18.6</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>% Caucasian</td>
<td>83.9</td>
</tr>
<tr>
<td>% African American</td>
<td>13.6</td>
</tr>
<tr>
<td>% other</td>
<td>2.5</td>
</tr>
<tr>
<td>Age, M (SD)</td>
<td>44.7 (11.1)</td>
</tr>
<tr>
<td>Cigarettes per day, M (SD)</td>
<td>21.4 (8.9)</td>
</tr>
<tr>
<td>No. of previous quit attempts, M (SD)</td>
<td>5.7 (9.7)</td>
</tr>
<tr>
<td>Fagerström Test for Nicotine Dependence, M (SD)</td>
<td>5.4 (2.1)</td>
</tr>
</tbody>
</table>

included medical contraindications to study medications, including heavy alcohol consumption (six drinks per day on 6 or 7 days of the week), history of seizure, schizophrenia, psychosis, an eating disorder, or bipolar disorder. In addition, participants could not be pregnant or breastfeeding and must have agreed to use adequate contraception. All participants were treated ethically. This study was approved by the University of Wisconsin Heath Sciences Institutional Review Board.

Procedure

Potential participants called into a central office to complete a phone screen. Those eligible were invited to an information session where they provided written, informed consent. Next, participants attended a screening visit where they were evaluated for possible exclusion criteria on the basis of a medical history screening, vital signs measurements (blood pressure over 160 systolic and/or 100 diastolic), and a carbon monoxide (CO) breath test. Additionally, participants completed several demographic, smoking history, and tobacco dependence questionnaires (e.g., the Fagerström Test for Nicotine Dependence [FTND]; Heatherton, Kozlowski, Frecker, & Fagerström, 1991). If participants met inclusion criteria, they completed two baseline sessions. During the first baseline session, participants completed additional assessments (e.g., a social network interview). At the second baseline session, participants came to the clinic after abstaining from cigarettes overnight in order to conduct medical assessments (e.g., serum lipid profiles, carotid intima media ultrasound, hemoglobin A1C).

Upon successful completion of the baseline assessment sessions, participants were randomized in a double-blind fashion blocked on gender and race (White/non-White). In addition to pharmacotherapy, all participants received six one-on-one counseling sessions, based on the basis of the Public Health Service guideline (e.g., decreasing smoking cues, increasing social support for nonsmoking; Fiore et al., 2008) lasting 10–20 min. Study staff who provided counseling and conducted study sessions were bachelor’s level, trained case managers supervised by a licensed clinical psychologist. Counselors were blind to placebo condition status (e.g., active patch vs. placebo patch) but not to medication type (e.g., bupropion vs. patch). Sessions occurred during 7 weeks, with the first counseling session occurring 1 week before the quit day and the subsequent five occurring on the quit day and at 1, 2, 4, and 8 weeks postquit.

The baseline visits occurred between 8 and 15 days prequit. Study visits occurred 1 week prequit, on the quit day, and 1, 2, 4, and 8 weeks postquit.

Treatment. Participants were randomized to one of six treatment conditions: (a) bupropion SR (150 mg, bid for 9 weeks total: 1 week prequit and 8 weeks postquit); (b) nicotine lozenge (recommended use of nine 2- or 4-mg lozenges per day, based on appropriate dose for dependence level per package instructions, for 12 weeks postquit); (c) nicotine patch (24-hr patch; 21, 14, and 7 mg; titrated down over 8 weeks postquit); (d) nicotine patch + nicotine lozenge combination therapy; (e) bupropion SR + nicotine lozenge combination therapy; or (f) placebo. Use instructions were consistent with the Food and Drug Administration (FDA) approved package insert instructions, and lozenge use instructions were the same in both monotherapy and combination therapy conditions. Those in the placebo condition were randomly assigned to one of five placebo conditions that matched the active treatments, with one fifth of participants receiving each condition (i.e., placebo bupropion, lozenge, patch, patch + lozenge, and bupropion + lozenge). There were no statistically significant differences between the active and placebo treatment groups on age, cigarettes smoked per day, FTND score, baseline CO level, gender, marital status, race, Hispanic origin, or education. Consistent with the FDA package instructions, participants on nicotine replacement products such as the lozenge and patch were instructed not to smoke while using nicotine replacement therapy (e.g., to remove the nicotine patch before smoking a cigarette).

Smoking status. Smoking status was collected using a smoking calendar whereby, at each contact, participants reported on their smoking each day since the last contact using the timeline follow-back (Brigham et al., 2008; Sobell, Sobell, Leo, & Cancilla, 1988). This differs from Shiffman et al. (2006) in that Shiffman et al. used ecological momentary assessment (EMA) to collect daily smoking data. However, the timeline follow-back procedure appears to be highly sensitive to whether people smoke (such as lapsing or relapsing), even though it is not as sensitive to fine-grained patterns of smoking as the EMA method (Lewis-Esquerre et al., 2005; Shiffman, 2009). Seven-day point-prevalence abstinence (“Have you smoked at all, even a puff, in the last 7 days?”) was assessed during the 8-week visit. Self-reports of smoking status were confirmed by a CO rating (<10 ppm). Follow-up interviewers were blind to treatment condition.

Data Analysis

Outcome variables. Three of the outcome variables were computed using the smoking calendar data. Participants were coded as having achieved initial abstinence if an individual reported smoking zero cigarettes on one or more days during the first
14 days of the study. The lapse variable was computed using data from only those individuals who achieved initial abstinence and was defined as the number of days between the first day where the participant smoked zero cigarettes and the first day where he or she smoked any amount (Shiffman et al., 2006). If individuals did not lapse, their lapse variable indicated the time from their quit date until the end of the 8-week follow-up period. If individuals withdrew from the study before lapsing, their lapse variable indicated the number of days from the quit date until the withdrawal date. Finally, the relapse variable was computed for all individuals who lapsed. The relapse variable was defined as the number of days from the lapse date until relapse day (the first of 7 consecutive days of smoking; Shiffman et al., 2006). If individuals lapsed but did not relapse, their relapse variable indicated the number of days from their lapse date until the end of the 8-week follow-up period. If they lapsed but withdrew from the study before relapsing, their relapse variable indicated the number of days from their lapse date until their withdrawal date. The results of these analyses were compared with CO-confirmed 7-day point-prevalence abstinence at 8 weeks post target quit date. It should be noted that the postprevalence abstinence results were reported in the main outcome article from this data set (Piper et al., 2009). This study had an a priori power of .88 to detect a clinically significant improvement in point-prevalence abstinence rates of 12%.

Tests of milestones. Analyses of initial abstinence were conducted using logistic regression. Failure to achieve initial cessation was coded as 1, and achieving initial cessation was coded as 0. Thus, odds ratios (ORs) below 1 indicate variables that improved rates of achievement of initial abstinence. Analyses of lapse and relapse were conducted using Cox proportional hazards regression survival analysis. Because proportional hazards regression results are interpreted as the risk of having an event (e.g., lapse) over time, results are discussed in terms of lapse risk and lapse–relapse risk (the risk of a relapse following a lapse). Individuals were censored from the analysis at the time of their last contact (e.g., their withdrawal date) if they did not have an event (e.g., lapse); all other participants who did not have an event were censored at the end of the follow-up period (8 weeks). In all of the survival analyses, having an event (e.g., lapse, relapse) was coded as 0; hazard ratios (HRs) below 1 were interpreted as beneficial for cessation.

We used an 8-week follow-up period because all treatments lasted at least 8 weeks postquit (the lozenge treatment lasted 12 weeks). This time point captures the longest time period for which intratreatment data were gathered for all active treatments. Because the goal of this research is to understand how medications influence the milestones, we do not report milestone outcomes after the medication had been discontinued. In support of this decision, when we examined the effect of the medication conditions on smoking cessation milestones during the 6-month follow-up period, the pattern of results was similar, though the effects were somewhat weaker.

Interactions with time. To test the Cox proportional hazards assumption and to determine whether the effect of treatment varied throughout the quit attempt, we examined interactions with time for the survival analyses. We computed the interaction between treatment condition and a variable representing time (e.g., Bupropion × Days to Lapse). Only significant interactions with time are reported.

Differential efficacy of pharmacotherapy treatments. All active medication conditions were compared with the placebo condition for each milestone. In addition, on the basis of a priori hypotheses that the combination pharmacotherapies would be superior to the monotherapies, we conducted planned comparisons between a composite variable coding all the monotherapies and a composite variable coding the combination treatments with the monotherapy condition as the reference group for each milestone. In addition, we compared the combination treatments with one another, with the bupropion + lozenge condition as the reference group.

Results

Achievement of Milestones

Of the 1,504 smokers enrolled in the study, 1,429 had complete calendar data for the first 14 days. Of those 1,429, 1,259 (88.1%) achieved initial abstinence (days to initial abstinence $M = 0.71$, $SD = 2.23$; $Mdn = 0$; $mode = 0$). Of the 1,259 who achieved initial abstinence, 785 (62.4%) had a lapse ($M = 11.54$ days, $SD = 14.63$; $Mdn = 5$ days; $mode = 1$ day). Of those 785 who lapsed, 252 (32.1%) relapsed (days to relapse $M = 21.66$, $SD = 17.04$; $Mdn = 17$; $mode = 2$; number of days from lapse to relapse $M = 7.49$, $SD = 7.80$, $Mdn = 6$; $mode = 0$). As reported in Piper et al. (2009), number and percentage rates of withdrawal from the study by treatment group during the treatment period were 9 (3%) for patch, 17 (7%) for lozenge, 6 (2%) for patch + lozenge, 9 (6%) for bupropion, 9 (3%) for bupropion + lozenge, and 13 (7%) for placebo. Progression through the milestones by treatment condition is detailed in Figure 1.

Treatment

Treatment was dummy coded for analysis. The comparison group was a combined group of all of the placebo conditions. Dummy-coded treatment variables were entered together as a set into the models for each of the outcomes. The results for each medication are discussed separately (see Table 2 for hazard ratios, $p$ values, and confidence intervals; see Figure 2 for lapse survival curves; see Figure 3 for relapse survival curves).³

Bupropion. Relative to placebo, bupropion reduced rates of failure to achieve initial abstinence and decreased lapse risk. Bupropion did not predict lapse–relapse risk. Bupropion reduced point-prevalence smoking rates relative to placebo.

---

¹ In the Shiffman et al. (2006) study, participants were given the entire length of the study (5 weeks) to achieve initial abstinence. However, because of the longer length of our study, we chose to limit the period for quitting to 2 weeks so as not to count fortuitous causes of abstinence for reasons such as hospitalization, international plane flights, and so forth.

² We also conducted Kaplan–Meier survival analyses. Because the results did not differ, we report only the Cox proportional hazards regression results.

³ Data analyses were conducted with and without controlling for gender and nicotine dependence (FTND score). The results did not change when covariates were entered. The unadjusted results are reported in Table 2.
Nicotine lozenge. Relative to placebo, the nicotine lozenge reduced rates of failure to achieve initial abstinence. The nicotine lozenge did not significantly decrease lapse risk, nor did it predict lapse–relapse risk. The nicotine lozenge reduced point-prevalence smoking rates relative to placebo.

Nicotine patch. Relative to placebo, the nicotine patch reduced rates of failure to achieve initial abstinence and decreased lapse risk and lapse–relapse risk. There was a significant interaction between nicotine patch and time to lapse such that the nicotine patch was less effective at preventing lapse later in the follow-up period (HR = 5.11, 95% CI [1.001, 1.01]). The nicotine patch reduced point-prevalence smoking rates relative to placebo.

Bupropion + lozenge. Relative to placebo, bupropion + lozenge reduced rates of failure to achieve initial abstinence and decreased lapse risk. Bupropion + lozenge decreased point-prevalence smoking rates relative to placebo.

Patch + lozenge. Relative to placebo, patch + lozenge reduced rates of failure to achieve initial abstinence and decreased lapse risk. Patch + lozenge did not predict lapse–relapse risk. Patch + lozenge decreased point-prevalence smoking rates relative to placebo.

Differential Efficacy of Pharmacotherapy Treatments

Initial abstinence. The combination treatments produced significantly lower rates of failure to achieve initial abstinence than did the monotherapies (OR = 0.61, 95% CI [0.41, 0.90]). Patch + lozenge produced significantly lower rates of failure to achieve initial abstinence than did the bupropion + lozenge (OR = 0.46, 95% CI [0.23, 0.92]).

Lapse. The combination treatments produced lower lapse risk than did the monotherapies (HR = 0.76, 95% CI [0.65, 0.89]) but did not differ from one another (p > .05).

Relapse. The combination treatments and monotherapies did not differ in reducing lapse–relapse risk (p > .05) and did not differ from one another (p > .05).

Point-prevalence abstinence. The combination treatments yielded lower point-prevalence smoking rates than did the mono-

Table 2
Results of Medication Conditions Predicting Smoking Cessation Milestones

<table>
<thead>
<tr>
<th>Medication</th>
<th>Failure to reach initial abstinence (n = 1,429)</th>
<th>Lapsea (n = 1,259)</th>
<th>Relapseb (n = 785)</th>
<th>8-week point-prevalence abstinence (N = 1,504)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>p</td>
<td>95% CI</td>
<td>HR</td>
</tr>
<tr>
<td>Bupropion</td>
<td>.54*</td>
<td>.02</td>
<td>[0.33, 0.89]</td>
<td>.74*</td>
</tr>
<tr>
<td>Lozenge</td>
<td>.45*</td>
<td>.002</td>
<td>[0.27, 0.75]</td>
<td>.80</td>
</tr>
<tr>
<td>Patch</td>
<td>.30*</td>
<td>&lt;.001</td>
<td>[0.17, 0.52]</td>
<td>.74*</td>
</tr>
<tr>
<td>Bupropion + lozenge</td>
<td>.36*</td>
<td>&lt;.001</td>
<td>[0.21, 0.62]</td>
<td>.58*</td>
</tr>
<tr>
<td>Patch + lozenge</td>
<td>.17*</td>
<td>&lt;.001</td>
<td>[0.09, 0.32]</td>
<td>.57*</td>
</tr>
</tbody>
</table>

Note. All significant effects remained significant after applying a Holm alpha correction for multiple comparisons, with the exception of the bupropion + lozenge condition predicting the lapse–relapse transition. All hazard ratios (HR) and odds ratios (OR) refer to comparisons between medication and placebo. CI = confidence interval.

*a Excludes individuals who did not achieve initial abstinence.  
*b Excludes individuals who did not lapse.

*p < .05.
therapies \((OR = 0.66, 95\% CI [0.53, 0.83])\) but did not differ from one another \((p > .05)\).

**Discussion**

The guiding hypothesis of this study was that the examination of meaningful components of the cessation process, or milestones (i.e., establishing initial abstinence, lapsing, and relapsing), can illuminate how treatments influence the transition from regular smoking to long-term abstinence. As was reported previously (Piper et al., 2009), all tested medications increased 8-week point-prevalence abstinence rates when compared with placebo, with combination treatments producing significantly higher abstinence rates than the monotherapies. The examination of cessation milestones revealed important information about the how these various medications resulted in these net effects on point-prevalence abstinence.

All the pharmacotherapy treatments increased the likelihood of initial cessation. As predicted, the combination therapies were particularly effective at producing high initial abstinence rates. The patch + lozenge combination was especially effective, producing initial abstinence rates that were significantly higher than those produced by the nicotine lozenge alone, bupropion alone, and the bupropion + lozenge combination. It was predicted that bupropion would produce the highest abstinence rates. However, although bupropion did increase initial abstinence relative to placebo treatment, it was far from the most effective agent. This may be because individuals were allowed 14 days to achieve initial abstinence, making the prequit administration of bupropion less important. On the other hand, nicotine replacement may be more effective than bupropion at reducing risk factors for early cessation failure such as craving and withdrawal.

Most smoking cessation medications were effective in reducing lapse risk following cessation, but the combination treatments tended to be more effective than the monotherapies (see Table 2). Contrary to predictions, the nicotine lozenge alone did not reduce lapse risk at 8 weeks postquit. This could be due to adherence. Perhaps, as found in other studies of PRN nicotine replacement therapies (Fortmann & Killen, 1995; Glover et al., 1996; Goldstein, Niaura, Follick, & Abrams, 1989), few participants took enough lozenges to reach a therapeutic dose. It is important to note that the nicotine lozenge did boost the efficacy of bupropion and the nicotine patch when taken in combination (see Table 2). Also, although the nicotine lozenge demonstrated significant increases in 8-week point-prevalence abstinence relative to placebo, it appeared to exert these effects by increasing initial abstinence rates, not by decreasing risks of lapse or relapse.

Although the cessation medications, on the whole, did influence initial cessation and lapse risk, few of them were significantly associated with the risk of relapse following a lapse. Only the nicotine patch and the bupropion + lozenge combination reduced relapse risk following a lapse during the 8-week treatment period. Bupropion alone, lozenge alone, and the patch + lozenge combination treatment did not affect the lapse–relapse transition. The finding that the medications produced relatively weak effects on relapse risk after a lapse was surprising given that Shiffman et al. (2006) found that this was the milestone most affected by the high-dose nicotine patch. A comparison of the effect sizes in the two studies illustrates the differences in findings. In Shiffman et
al., those on the high-dose nicotine patch were 1.3 times more likely to achieve initial abstinence, whereas in our study those in the medication conditions were 1.85 (bupropion) to 5.8 times (patch + lozenge) more likely to achieve initial abstinence than those on placebo. The medications in the current study showed similar effect sizes to the Shiffman et al. study with respect to reducing lapse risk (Shiffman et al. 1.60 vs. 1.25 [lozenge] to 1.75 [patch + lozenge] in our study) but smaller effects with regard to lapse–relapse transition. In the Shiffman et al. study, those taking placebo were 4.8 times more likely to relapse following a lapse than those on the high-dose nicotine patch, whereas in our study those on placebo were 1.31 (bupropion) to 1.92 (patch) times more likely to relapse than those in the active medication conditions. Therefore, in the present research the five medications exerted relatively large effects on attainment of initial abstinence and more modest effects on preventing relapse.

Differences in the pattern of results in the two studies could be due to multiple factors. For example, differences in the duration of the follow-up period analyzed might have affected the results. It is also possible that the high-dose nicotine patch is particularly effective in reducing lapse–relapse progression. Also, an absence of statistically significant effects on relapse rates in the present study can be attributed, in part, to low statistical power, because only lapsers were available for such analyses. However, an examination of effect sizes shows that the interventions all exerted larger effects on the early, initial abstinence mark than on the later outcomes (e.g., the lapse–relapse latency).

It is important to note that, when we examined effects over 6 months postquit (rather than 8 weeks), the pattern of results was similar, but the effects were weaker. For instance, prediction of lapse remained significant for all treatment conditions, but none of the treatment conditions was associated with the risk of a relapse following a lapse. Thus, across both durations of follow-up, the general pattern of results is consistent with earlier suggestions that the beneficial effects of cessation medications tend to be manifested early in the course of treatment (e.g., in facilitating the initial achievement of abstinence; see Hughes & Callas, 2006; Hughes, Gust, Keenan, Fenwick, & Healey, 1989; Piasecki et al., 2002) and that once treatment has ended, treatment effects abate (Medioni, Berlin, & Mallet, 2005).

### Implications for Treatment

The above findings have relevance for smoking cessation treatment. Our data suggest that early cessation success may provide a highly informative surrogate outcome for evaluating cessation medications, one that permits efficient, early evaluation of treatments and that permits treatment adjustment based upon initial effects (e.g., in accordance with a sequential multiple assignment randomized trial design in which treatment is altered if an individual does not achieve initial abstinence; Murphy, 2005). The present findings also underscore the need to develop treatments that more effectively reduce relapse likelihood following a lapse.

### Limitations and Future Directions

The method of examining milestones for only individuals who reached a previous milestone may introduce bias in the data when
comparing across conditions. For example, if one medication were particularly good at helping smokers achieve initial abstinence, then the smokers entered into the lapse analyses in this condition may differ in important ways from those entered into that analysis for the placebo condition. Therefore, after the initial cessation analysis, it is possible that the treatments were not being compared using a level playing field. For instance, the nicotine patch + lozenge condition may have had relatively weak effects on relapse because it was so effective in preventing lapses; that is, only the most vulnerable individuals lapsed with this treatment, and therefore they were especially susceptible to eventual, full relapse. This problem makes it difficult to compare treatments on the later milestones and reduces the strength of inferences from such inter-treatment contrasts. Also, adherence to medications may have been an issue for analyses of later time points, particularly after participants began to lapse. This may have been compounded by the package instructions for nicotine replacement therapies that told patients not to smoke while using these medications, which may have encouraged discontinuation of medication use. We had limited ability to assess adherence in this research because medication adherence data were collected only at visits, and these occurred infrequently at later time points. Also, the current research examined only a subset of cessation medications; it will be important to use milestones to examine additional medications such as varenoline. One additional limitation is that some smoking measures (e.g., relapse date) were not individually verified using biochemical confirmation. However, point-prevalence reports of smoking were consistently validated by CO assays, and relapse status (among those who lapsed) evaluated at 6 months postquit was correlated with CO-confirmed point-prevalence abstinence ($r = .51, p < .001$).

**Summary and Conclusions**

This research yielded the following findings: (a) Smoking cessation medications are quite effective at promoting initial abstinence and reducing lapse risk, but the evidence is weaker that they prevent a transition from lapse to relapse. (b) The combination pharmacotherapies tested tended to be superior to the monotherapies in maintaining attainment of initial abstinence and prevention of lapse. The nicotine patch + lozenge was superior to bupropion + lozenge in producing initial abstinence.

A final observation is that an examination of milestones did afford useful information that could not be inferred from point-prevalence abstinence rates per se. For instance, these analyses revealed that large differences in point-prevalence abstinence observed at 8 weeks postquit could be attributed, in good part, to effects on initial cessation that occur within 2 weeks of the quit attempt (see Figure 1). Conversely, treatments that differ greatly on 8-week point-prevalence abstinence are essentially equivalent in terms of protecting against lapse–relapse progression. Therefore, the results presented in this article, as well as those produced by Shiffman et al. (2006), support the utility of this more comprehensive approach to understanding the process of relapse and identifying where in this process treatments are exerting their effects.

**References**


Received February 11, 2010
Revision received August 9, 2010
Accepted September 8, 2010